普罗布考联合阿司匹林治疗重度大脑中动脉M1段狭窄的临床效果

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (32 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨普罗布考联合阿司匹林治疗重度大脑中动脉M1 段狭窄的临床效果及安全性。方法选取2017年1月至2019年12月福建医科大学附属泉州市第一医院收治的重度大脑中动脉M1 狭窄100 例患者，按照随机数字表法将其分为对照组和试验组，每组各50 例。对照组采用阿司匹林治疗，试验组在对照组的基础上给予普罗布考0.5 g/次，bid，连续治疗3 个月。比较两组的大脑中动脉M1 段狭窄好转率、血脂水平及药物不良反应发生情况。结果治疗后，试验组的大脑中动脉M1 狭窄程度为（62.03±2.15）%，低密度脂蛋白胆固醇（LDL-C）为（2.37±0.17）mmol/L，三酰甘油（TG）为（1.18±0.14）mmol/L，总胆固醇为（3.06±0.12）mmol/L，纤维蛋白原（FIB）为（2.34±0.34）g/L，分别低于对照组的（71.85±2.77）%、（3.37±0.2）mmol/L、（2.09±0.12）mmol/L、（5.02±0.12）mmol/L 和（3.88±0.23）g/L，高密度脂蛋白胆固醇（HDL-C）为（1.21±0.09）mmol/L，高于对照组的（1.11±0.09）mmol/L，凝血酶原时间（PT）为（18.54±2.01）s，活化凝血酶原时间（APTT）为（32.36±2.72）s，长于对照组的（15.06±1.63）s 和（25.44±2.43）s，差异均有统计学意义（P＜0.05）。两组治疗期发生药物不良反应，试验组表现呕吐、腹胀，对照组表现呕吐，两组的不良反应发生率比较，差异无统计学意义（P＞0.05）。结论普罗布考治疗重度大脑中动脉M1 段狭窄的临床效果确切，可显著改善大脑中动脉狭窄程度，且不增加药物不良反应发生率。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄文立
	洪全龙
	吴志生
	朱志华
	宫淑杰

关键词 ：普罗布考, 大脑中动脉, 阿司匹林, 临床效果, 安全性

Abstract：Objective To investigate the clinical effect and safety of Probucol combined with Aspirin in the treatment of severe M1 segment stenosis of middle cerebral artery.Methods A total of 100 patients with severe M1-stenosis admitted to Quanzhou First Hospital Affiliated to Fujian Medical University from January 2017 to December 2019 were selected and divided into the control group and the experimental group according to random number table method, 50 cases in each group.The control group was given Aspirin treatment only, and the experimental group was given Probucol 0.5 g/time, bid, for 3 months on the basis of treatment in the control group.The M1 segment stenosis degree, lipid level and adverse drug reactions were compared between the two groups.Results The M1 stenosis degree of the experimental group was (62.03±2.15) %, low-density lipoprotein-cholesterol (LDL-C) was (2.37±0.17) mmol/L, triacylglycerol（TG） was (1.18±0.14) mmol/L, total cholesterol（TC） was (3.06±0.12) mmol/L and fibrinogen (FIB) was (2.34±0.34) g/L,respectively, lower than that of the control group of (71.85±2.77) %, (3.37±0.2) mmol/L, (2.09±0.12) mmol/L, (5.02±0.12) mmol/L and (3.88±0.23) g/L, high-density lipoprotein cholesterol (HDL-C) was (1.21±0.09) mmol/L, higher than that of the control group of (1.11±0.09) mmol/L, prothrombin time (PT) was (18.54±2.01） s, acti vatedpartial thromboplastin time (APTT) was (32.36±2.72）s, longer than tthat of the control group of (15.06±1.63) and (25.44±2.43) s, the differences were statistically significant (P＜0.05).Adverse drug reactions occurred in the two groups during treatment,including vomiting and abdominal distension in the experimental group and vomiting in the control group.There was no statistically significant difference in the incidence of adverse reaction (P＞0.05).Conclusion Probucol in the treatment of severe M1-segment of middle cerebral artery can significantly improve the degree of stenosis of middle cerebral artery，without increasing the incidence of adverse drug reactions.

Key words： Probucol Middle cerebral artery Aspirin Clinical effect Security

引用本文:

黄文立；洪全龙；吴志生；朱志华；宫淑杰. 普罗布考联合阿司匹林治疗重度大脑中动脉M1段狭窄的临床效果[J]. 中国当代医药, 2021, 28(29): 71-73转77.
HUANG Wen-li；HONG Quan-long；WU Zhi-sheng；ZHU Zhi-hua；GONG Shu-jie. Clinical effect of Probukol combined with Aspirin in the treatment of severe M1 segment stenosis of middle cerebral artery. 中国当代医药, 2021, 28(29): 71-73转77.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I29/71

[1]	陈康宁，王伊龙，王拥军，等.2018 症状性动脉粥样硬化性非急性颅内大动脉闭塞血管内治疗中国专家共识[J].中国卒中杂志，2018，13（11）：1167-1181.
[2]	Lu SS，Ge S，Su CQ，et al.MRI of plaque characteristics and relationship with downstream perfusion and cerebral infarction in patients with symptomatic middle cerebral artery stenosis[J].J Magn Reson Imaging，2018，48（1）：66-73.
[3]	Wu F，Song H，Ma，et al.Hyperintense Plaque on Intracranial Vessel Wall Magnetic Resonance Imaging as a Predictor of Artery-to-Artery Embolic Infarction[J].Stroke，2018，49（4）：905-911.
[4]	Rotzinger DC，Mosimann PJ，Meuli RA，et al.Site and Rate of Occlusive Disease in Cervicocerebral Arteries：A CT Angiography Study of 2209 Patients with Acute Ischemic Stroke[J].AJNR Am J Neuroradiol，2017，38（5）：868-874.
[5]	Kim BJ，Kim SM，Kang DW，et al.Vascular tortuosity may be related to intracranial artery atherosclerosis[J].Int J Stroke，2015，10（7）：1081-1086.
[6]	Yu YN，Li ML，Xu YY，et al.Middle cerebral artery geometric features are associated with plaque distribution and stroke[J].Neurology，2018，91（19）：e760-e769.
[7]	Cheng L，Jiao L，Gao，et al.Risk factors associated with inhospital serious adverse events after stenting of severe symptomatic intracranial stenosis[J].Clin Neurol Neurosurg，2016，147：59-63.
[8]	Wang Y，Zhao X，Liu L，et al.P revalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China：the Chinese Intracranial Atherosclerosis （CICAS） Study[J].Stroke，2014，45（3）：663-669.
[9]	董晓柳，朱丽霞，徐士军.普罗布考联合瑞舒伐他汀对脑梗死合并糖尿病患者颈动脉粥样硬化、血脂及炎症因子的影响[J].中国动脉硬化杂志，2016，24（2）：177-181.
[10]	Zhang M，Hou Y，Shen，et al.Probucol reverses homocysteine induced inflammatory monocytes differentiation and oxidative stress[J].Eur J Pharmacol，2018，818：67-73.
[11]	Yakushiji E，Ayaori M，Nishida T，et al.Probucol-Oxidized Products，Spiroquinone and Diphenoquinone，Promote Reverse Cholesterol Transport in Mice[J].Arterioscler Thromb Vasc Biol，2016，36（4）：591-597.
[12]	Kim BJ，Lee EJ，Kwon SU，et al.Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage （PICASSO）：a multicentre，randomised controlled trial[J].Lancet Neurol，2018，17（6）：509-518.
[13]	Hong KS，Kim BJ，Lee JY，et al.Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage （PICASSO） study：A randomized controlled trial[J].Int J Stroke，2015，10（7）：1153-1158.
[14]	蔡永强.补中益气汤联合阿托伐他汀治疗脑梗塞并高血脂的疗效观察及其对血液流变学的影响[J].中国中医药科技，2016，23（1）：71-72.
[15]	甘解华，汪咏秋.普罗布考对老年脑梗死进展期患者疗效、APTT、纤维蛋白原及神经功能缺损的影响[J].中国老年学杂志，2019，4（2）：781-783.